These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Sunitinib-induced subungual splinter haemorrhage and acral erythema. Nakamura M; Miyachi Y Eur J Dermatol; 2008; 18(3):344-5. PubMed ID: 18474471 [No Abstract] [Full Text] [Related]
29. Acute renal failure during the "off" period after sunitinib administration: possible mechanism of vascular endothelial growth factor cascade hyperactivation. Kato T; Tomita Y; Watanabe T Int J Urol; 2013 Nov; 20(11):1149-50. PubMed ID: 23659419 [No Abstract] [Full Text] [Related]
30. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib. Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103 [No Abstract] [Full Text] [Related]
31. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. van den Meiracker AH; Danser AH; Sleijfer S; Kappers MH J Natl Cancer Inst; 2011 Oct; 103(20):1557; author reply 1558. PubMed ID: 21862728 [No Abstract] [Full Text] [Related]
32. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116 [TBL] [Abstract][Full Text] [Related]
33. Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons. Catalá-López F Eur J Cancer; 2013 Mar; 49(4):984-5. PubMed ID: 23140823 [No Abstract] [Full Text] [Related]
35. Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate. Lim TJ; Lee JH; Chang SG; Lee CH; Min GE; Yoo KH; Jeon SH Urol Int; 2010; 85(4):475-8. PubMed ID: 20975258 [TBL] [Abstract][Full Text] [Related]
36. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease. Guenova E; Weber HO; Voykov B; Metzler G; Mitev V; Berneburg M; Hoetzenecker W; Röcken M Arch Dermatol; 2008 Aug; 144(8):1081-2. PubMed ID: 18711102 [No Abstract] [Full Text] [Related]
37. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. van der Veldt AA; van den Eertwegh AJ; Hoekman K; Barkhof F; Boven E Ann Oncol; 2007 Oct; 18(10):1747-50. PubMed ID: 17890217 [No Abstract] [Full Text] [Related]
38. Sunitinib-induced acute hemolysis without hypertension: a case report. Jain R; Mathew P; Wood CG; Tannir NM Clin Genitourin Cancer; 2008 Sep; 6(2):122-3. PubMed ID: 18824436 [TBL] [Abstract][Full Text] [Related]
39. New therapeutic options for renal cell carcinoma. Stadler W Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664 [No Abstract] [Full Text] [Related]